The UK sleep-wake disorder market is estimated to grow at a CAGR of 6.2% during the forecast period. UK contributes a considerable share in the market due to the presence of a significant number of people with behavioural health disorders and the growing awareness of sleep disorders in the country. Mental Health First Aid (MHFA) England is a social organization that offers expert guidance and training to support mental health. According to the MHFA statistics 2019, 1 in 4 people faces mental health issues each year and responsible for 72 million working days lost and costs $45.5 billion each year. Additionally, 1 in 6 workers experience depression, anxiety or problems relating to stress at any one time and 526,000 cases of work-related stress, depression or anxiety were recorded in 2016-2017 in Great Britain as per MHFA. In 2016-2017, stress was responsible for 40% of all cases of work-related ill health and for 49% of all working days lost due to health issues in the country as per MHFA. Therefore, work-related stress raises the risk of sleep disorders that further increases the demand for effective treatment.
To Request a Sample of our Report on UK Sleep-Wake Disorder Market: https://www.omrglobal.com/request-sample/uk-sleep-wake-disorder-market
The market is segmented on the basis of type and treatment. Based on type, the market is sub-segmented into insomnia, hypersomnia, sleep apnea, circadian rhythm disorders, and others. Sleep apnea holds the largest market share during the forecast period. On the basis of treatment, the market is divide into therapies, drugs, and devices. The sleep-wake disorder devices segment is estimated to hold the largest market share during the forecast period, followed by medications. Some of the players operating in the market include Koninklijke Philips N.V, Medtronic PLC, Sanofi SA, Jazz Pharmaceutical Inc., and others.
In January 2020, Jazz Pharmaceuticals, SK Biopharmaceutical’s US partner received sales approval from the European Medicine Agency (EMA) for Sunosi (Ingredient: solriamfetol), a treatment for improving wakefulness in patients suffering from excessive daytime sleepiness related with narcolepsy or obstructive sleep apnea. SK Biopharmaceutical discovered Sunosi and completed its phase 1 clinical trial before licensing out the substance to Aerial BioPharma in 2011. Thereafter, Jazz Pharmaceuticals took over the global commercialization rights, including the US and Europe, for completing the phase 3 clinical trials for the drug. With this approval, Jazz Pharma has planned to launch Sunosi in Germany in mid-2020 and then to France and UK by early 2021.
(Get 15% Discount on Buying this Report)
A full Report of UK Sleep-Wake Disorder Market is Available at: https://www.omrglobal.com/industry-reports/uk-sleep-wake-disorder-market
UK Sleep-Wake Disorder Market Segmentation
By Type
· Insomnia
· Hypersomnia
· Circadian Rhythm Disorders
· Others
By Treatment
· Therapies
· Drugs
· Devices
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
